SCI
RPRX icon

S&CO Inc’s Royalty Pharma RPRX Stock Holding History

S&CO Inc’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Sell
358,302
-75
-0% -$3.9K 1.16% 22
2026
Q1 		$17.2M Hold
358,377
– – 1.07% 24
2025
Q4 		$13.8M Buy
358,377
+140
+0% +$5.34K 0.86% 31
2025
Q3 		$12.6M Buy
358,237
+70
+0% +$2.53K 0.77% 34
2025
Q2 		$12.9M Hold
358,167
– – 0.83% 31
2025
Q1 		$11.1M Buy
358,167
+5
+0% +$158 0.75% 34
2024
Q4 		$9.14M Sell
358,162
-4,323
-1% -$115K 0.62% 43
2024
Q3 		$10.3M Buy
362,485
+4,220
+1% +$117K 0.67% 38
2024
Q2 		$9.45M Buy
358,265
+17,210
+5% +$477K 0.66% 38
2024
Q1 		$10.4M Buy
341,055
+8,945
+3% +$264K 0.73% 35
2023
Q4 		$9.33M Buy
332,110
+78,500
+31% +$2.16M 0.72% 34
2023
Q3 		$6.88M Buy
253,610
+29,390
+13% +$873K 0.57% 42
2023
Q2 		$6.89M Buy
224,220
+71,290
+47% +$2.41M 0.56% 41
2023
Q1 		$5.51M Sell
152,930
-6,985
-4% -$259K 0.47% 47
2022
Q4 		$6.32M Hold
159,915
– – 0.55% 42
2022
Q3 		$6.42M Hold
159,915
– – 0.58% 38
2022
Q2 		$6.72M Buy
159,915
+20
+0% +$820 0.57% 39
2022
Q1 		$6.23M Buy
159,895
+14,660
+10% +$576K 0.44% 48
2021
Q4 		$5.79M Buy
145,235
+52,385
+56% +$2.04M 0.41% 49
2021
Q3 		$3.35M Buy
92,850
+31,590
+52% +$1.23M 0.26% 73
2021
Q2 		$2.51M Buy
61,260
+2,520
+4% +$107K 0.2% 91
2021
Q1 		$2.56M Buy
58,740
+1,100
+2% +$52.2K 0.22% 81
2020
Q4 		$2.88M Buy
57,640
+26,490
+85% +$1.12M 0.26% 74
2020
Q3 		$1.31M Buy
+31,150
New +$1.34M 0.13% 100

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

S&CO Inc's RPRX Position: Q2 2026 in Review

S&CO Inc reduced its Royalty Pharma (RPRX) stake by 0.02% in Q2 2026, selling an estimated $3.9K and leaving 358,302 shares worth $20.1M. The position accounts for 1.16% of the portfolio, ranked #22.

S&CO Inc first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • S&CO Inc held 358,302 shares of Royalty Pharma worth $20.1M as of Q2 2026.
  • S&CO Inc sold 75 Royalty Pharma shares in Q2 2026, an estimated $3.9K.
  • Royalty Pharma made up 1.16% of S&CO Inc's portfolio in Q2 2026, its #22 holding.
  • S&CO Inc first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.